Search research articles
Contact Us
Filters
Showing results (31-40 of 110) with videos related to
Page
of 11
Sort By:
Addictive Behaviors
|
May 15, 2018
A statewide effort to reduce high-dose opioid prescribing through coordinated care organizations
Daniel M Hartung, Lindsey Alley, Gillian Leichtling, et al.
Pain Medicine (Malden, Mass.)
|
October 9, 2025
Impact of Prescription Drug Monitoring Program Integration in the Electronic Health Record on High-Risk Opioid Prescribing in Primary Care
Daniel M Hartung, Sanae El Ibrahimi, Michelle A Hendricks, et al.
Multiple Sclerosis and Related Disorders
|
November 26, 2024
Multiple sclerosis disease-modifying therapy use in the department of veteran affairs and Medicare: A comparative analysis
Daniel M Hartung, Glenn D Graham, Mitchell Wallin, et al.
Journal of General Internal Medicine
|
April 20, 2005
Clinical implications of an accurate problem list on heart failure treatment
Daniel M Hartung, Jacquelyn Hunt, Joseph Siemienczuk, et al.
Pharmacotherapy
|
September 28, 2005
Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study
Daniel M Hartung, Daniel R Touchette, Nanette C Bultemeier, et al.
Neurology. Clinical Practice
|
September 26, 2022
Association Between Pharmacy Benefit Restrictions and Disease-Modifying Therapy Use in the Medicare Part D Program
Daniel M Hartung, Kirbee A Johnston, Jessina C McGregor, et al.
Neurology
|
April 26, 2015
The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
Daniel M Hartung, Dennis N Bourdette, Sharia M Ahmed, et al.
Multiple Sclerosis and Related Disorders
|
October 8, 2020
The effect of out-of-pocket costs on initiation of disease-modifying therapies among medicare beneficiaries with multiple sclerosis
Daniel M Hartung, Kirbee A Johnston, Jessina C McGregor, et al.
Journal of Managed Care & Specialty Pharmacy
|
June 29, 2021
Effect of relaxing hepatitis C treatment restrictions on direct-acting antiviral use in a Medicaid program: an interrupted time series analysis
Megan C Herink, Jonah Geddes, Kim Vo, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
February 16, 2019
Repository Corticotropin Versus Glucocorticoid for Nephrotic Syndrome: When Will We See the Evidence?
Daniel M Hartung, Kirbee Johnston, Atul Deodhar, et al.
Page
of 11
Search research articles
Search
Showing results (31-40 of 110) with videos related to
Sort By:
Page
of 11
Addictive Behaviors
|
May 15, 2018
A statewide effort to reduce high-dose opioid prescribing through coordinated care organizations
Daniel M Hartung, Lindsey Alley, Gillian Leichtling, et al.
Pain Medicine (Malden, Mass.)
|
October 9, 2025
Impact of Prescription Drug Monitoring Program Integration in the Electronic Health Record on High-Risk Opioid Prescribing in Primary Care
Daniel M Hartung, Sanae El Ibrahimi, Michelle A Hendricks, et al.
Multiple Sclerosis and Related Disorders
|
November 26, 2024
Multiple sclerosis disease-modifying therapy use in the department of veteran affairs and Medicare: A comparative analysis
Daniel M Hartung, Glenn D Graham, Mitchell Wallin, et al.
Journal of General Internal Medicine
|
April 20, 2005
Clinical implications of an accurate problem list on heart failure treatment
Daniel M Hartung, Jacquelyn Hunt, Joseph Siemienczuk, et al.
Pharmacotherapy
|
September 28, 2005
Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study
Daniel M Hartung, Daniel R Touchette, Nanette C Bultemeier, et al.
Neurology. Clinical Practice
|
September 26, 2022
Association Between Pharmacy Benefit Restrictions and Disease-Modifying Therapy Use in the Medicare Part D Program
Daniel M Hartung, Kirbee A Johnston, Jessina C McGregor, et al.
Neurology
|
April 26, 2015
The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
Daniel M Hartung, Dennis N Bourdette, Sharia M Ahmed, et al.
Multiple Sclerosis and Related Disorders
|
October 8, 2020
The effect of out-of-pocket costs on initiation of disease-modifying therapies among medicare beneficiaries with multiple sclerosis
Daniel M Hartung, Kirbee A Johnston, Jessina C McGregor, et al.
Journal of Managed Care & Specialty Pharmacy
|
June 29, 2021
Effect of relaxing hepatitis C treatment restrictions on direct-acting antiviral use in a Medicaid program: an interrupted time series analysis
Megan C Herink, Jonah Geddes, Kim Vo, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
February 16, 2019
Repository Corticotropin Versus Glucocorticoid for Nephrotic Syndrome: When Will We See the Evidence?
Daniel M Hartung, Kirbee Johnston, Atul Deodhar, et al.
Page
of 11